Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.60 |
| ▸ | MMP2 | P08253 | 5/20 | 0.58 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.56 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.56 |
| ▸ | CCKAR | P32238 | 4/20 | 0.52 |
| ▸ | CCKBR | P32239 | 4/20 | 0.52 |
| ▸ | MMP9 | P14780 | 3/20 | 0.52 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926755 | 1.00 | KCNA5 (0.60) | KCNA5MMP2ADAMTS5ITGB1ITGA4 | |
| SCHEMBL3971077 | 0.90 | ADAMTS5 (0.50) | MMP2ADAMTS5 | |
| SCHEMBL5926646 | 0.89 | MCL1 (0.56) | KCNA5MMP2ADAMTS5ITGB1ITGA4 | |
| SCHEMBL6100413 | 0.87 | — | — | |
| SCHEMBL5927388 | 0.87 | MMP2 (0.60) | MMP2ADAMTS5ITGB1ITGA4CCKAR | |
| SCHEMBL3993279 | 0.87 | KCNA5 (0.48) | KCNA5ITGB1ITGA4 | |
| SCHEMBL5926865 | 0.84 | ACLY (0.52) | MMP2ITGB1ITGA4CCKARCCKBR | |
| SCHEMBL5927106 | 0.84 | CCKAR (0.53) | KCNA5MMP2ADAMTS5ITGB1ITGA4 | |
| SCHEMBL5926727 | 0.84 | MMP2 (0.52) | KCNA5MMP2ADAMTS5ITGB1ITGA4 | |
| SCHEMBL5926248 | 0.84 | KCNA5 (0.52) | KCNA5MMP2ITGB1ITGA4CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |